Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival.

Russell B, Sherif A, Häggström C, Josephs D, Kumar P, Malmström PU, Van Hemelrijck M.

Scand J Urol. 2019 Jun 7:1-7. doi: 10.1080/21681805.2019.1624611. [Epub ahead of print]

PMID:
31174452
2.

How to measure temporal changes in care pathways for chronic diseases using health care registry data.

Ventimiglia E, Van Hemelrijck M, Lindhagen L, Stattin P, Garmo H.

BMC Med Inform Decis Mak. 2019 May 30;19(1):103. doi: 10.1186/s12911-019-0823-y.

4.

Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma.

Nakamura M, Bax HJ, Scotto D, Souri EA, Sollie S, Harris RJ, Hammar N, Walldius G, Winship A, Ghosh S, Montes A, Spicer JF, Van Hemelrijck M, Josephs DH, Lacy KE, Tsoka S, Karagiannis SN.

Oncoimmunology. 2019 Mar 28;8(6):e1593811. doi: 10.1080/2162402X.2019.1593811. eCollection 2019.

5.

Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort.

Essén A, Santaolalla A, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M.

Cancer Causes Control. 2019 Jun;30(6):603-615. doi: 10.1007/s10552-019-01170-6. Epub 2019 Apr 24.

PMID:
31020446
6.

Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.

Häggström C, Garmo H, de Luna X, Van Hemelrijck M, Söderkvist K, Aljabery F, Ströck V, Hosseini A, Gårdmark T, Malmström PU, Jahnson S, Liedberg F, Holmberg L.

Cancer Med. 2019 May;8(5):2196-2204. doi: 10.1002/cam4.2126. Epub 2019 Apr 1.

7.

The burden of urological cancers in low- and middle-income countries.

Van Hemelrijck M.

BJU Int. 2019 Apr;123(4):557. doi: 10.1111/bju.14641. No abstract available.

PMID:
30854799
8.

Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis.

Buzzatti N, Van Hemelrijck M, Denti P, Ruggeri S, Schiavi D, Scarfò IS, Reser D, Taramasso M, Weber A, La Canna G, De Bonis M, Maisano F, Alfieri O.

J Thorac Cardiovasc Surg. 2019 Jan 22. pii: S0022-5223(19)30232-6. doi: 10.1016/j.jtcvs.2019.01.023. [Epub ahead of print]

PMID:
30797588
9.

Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.

George G, Scailteux LM, Garmo H, Balusson F, Cardwell C, Coster G, Schutter H, Kuiper JG, McMenamin Ú, Verbeeck J, Van Hemelrijck M.

Fundam Clin Pharmacol. 2019 Feb 18. doi: 10.1111/fcp.12454. [Epub ahead of print]

PMID:
30776136
10.

Brief behavioural intervention, delivered as standard care, to support physical activity engagement in men with prostate cancer: a pilot study protocol.

Fox L, Wiseman T, Cahill D, Fleure L, Kinsella J, Van Hemelrijck M.

BMJ Open Sport Exerc Med. 2018 Dec 17;4(1):e000469. doi: 10.1136/bmjsem-2018-000469. eCollection 2018.

11.

Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method.

Bessa A, Maclennan S, Enting D, Bryan R, Josephs D, Hughes S, Amery S, Khan MS, Malde S, Nair R, Cahill F, Wylie H, Thurairaja R, Chatterton K, Kinsella N, Häggström C, Van Hemelrijck M.

Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30075-2. doi: 10.1016/j.eururo.2019.01.031. [Epub ahead of print] No abstract available.

PMID:
30712969
12.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jul;124(1):87-92. doi: 10.1111/bju.14666. Epub 2019 Feb 6.

PMID:
30637900
13.

Patients' perspectives on opt-out consent for observational research: systematic review and focus group.

Cardillo L, Cahill F, Wylie H, Williams A, Zylstra J, Davies A, Fullwood L, Van Hemelrijck M.

Br J Nurs. 2018 Dec 13;27(22):1321-1329. doi: 10.12968/bjon.2018.27.22.1321.

PMID:
30525978
14.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26.

PMID:
30497883
15.

Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?

Van Hemelrijck M, Sollie S, Nelson WG, Yager JD, Kanarek NF, Dobs A, Platz EA, Rohrmann S.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):578-583. doi: 10.1158/1055-9965.EPI-18-0520. Epub 2018 Nov 27.

PMID:
30482876
16.

Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?

Ghoshal A, Garmo H, Hammar N, Jungner I, Malmström H, Walldius G, Van Hemelrijck M.

BMC Cancer. 2018 Nov 26;18(1):1169. doi: 10.1186/s12885-018-5098-7.

17.

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M.

Cancer Causes Control. 2019 Feb;30(2):195-206. doi: 10.1007/s10552-018-1093-1. Epub 2018 Nov 12.

PMID:
30421156
18.

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium.

Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29.

PMID:
30385049
19.

Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.

Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, Van Hemelrijck M.

Acta Oncol. 2019 Jan;58(1):110-118. doi: 10.1080/0284186X.2018.1529427. Epub 2018 Oct 30.

PMID:
30375907
20.

Occupational exposure and risk of testicular cancer: what can an ecological study in the Nordic countries tell us?

Van Hemelrijck M.

BJU Int. 2018 Sep;122(3):351. doi: 10.1111/bju.14180. No abstract available.

PMID:
30187659
21.

Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma.

Knight WRC, Zylstra J, Wulaningsih W, Van Hemelrijck M, Landau D, Maisey N, Gaya A, Baker CR, Gossage JA, Largergren J, Davies AR; Guy's and St Thomas' Oesophago‐Gastric Research Group.

BJS Open. 2018 Apr 23;2(4):229-237. doi: 10.1002/bjs5.65. eCollection 2018 Aug.

22.

Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.

Davies AR, Myoteri D, Zylstra J, Baker CR, Wulaningsih W, Van Hemelrijck M, Maisey N, Allum WH, Smyth E, Gossage JA, Lagergren J, Cunningham D, Green M; Guy's and St Thomas' Oesophago-Gastric Research Group and PROGRESS Study Group.

Br J Surg. 2018 Nov;105(12):1639-1649. doi: 10.1002/bjs.10900. Epub 2018 Jul 26.

PMID:
30047556
23.

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, Van Hemelrijck M, Lambe M.

Breast Cancer Res Treat. 2018 Nov;172(1):167-177. doi: 10.1007/s10549-018-4890-z. Epub 2018 Jul 21.

24.

Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy.

Knight WRC, Zylstra J, Van Hemelrijck M, Griffin N, Jacques AET, Maisey N, Baker CR, Gossage JA, Largergren J, Davies AR.

BJS Open. 2018 Mar 15;1(6):182-190. doi: 10.1002/bjs5.30. eCollection 2017 Dec.

25.

Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria.

Van Hemelrijck M, Ulmer H, Nagel G, Peter RS, Fritz J, Myte R, van Guelpen B, Föger B, Concin H, Häggström C, Stattin P, Stocks T.

PLoS One. 2018 Jun 13;13(6):e0197830. doi: 10.1371/journal.pone.0197830. eCollection 2018.

26.

Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus.

Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L.

Int J Cancer. 2018 Oct 15;143(8):1868-1875. doi: 10.1002/ijc.31587. Epub 2018 Aug 10.

27.

Cognitive training for technical and non-technical skills in robotic surgery: a randomised controlled trial.

Raison N, Ahmed K, Abe T, Brunckhorst O, Novara G, Buffi N, McIlhenny C, van der Poel H, van Hemelrijck M, Gavazzi A, Dasgupta P.

BJU Int. 2018 Dec;122(6):1075-1081. doi: 10.1111/bju.14376. Epub 2018 Jun 12.

PMID:
29733492
28.

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M.

PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018.

29.

Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M.

Eur Urol. 2018 Sep;74(3):261-280. doi: 10.1016/j.eururo.2018.02.026. Epub 2018 Mar 26.

PMID:
29598981
30.

Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.

Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, Van Hemelrijck M.

Transl Androl Urol. 2018 Feb;7(1):83-97. doi: 10.21037/tau.2017.12.24. Review.

31.

The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.

Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S.

Urol Oncol. 2018 Jun;36(6):309.e15-309.e23. doi: 10.1016/j.urolonc.2018.02.016. Epub 2018 Mar 22.

PMID:
29576269
32.

Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

Nowinski S, Santaolalla A, O'Leary B, Loda M, Mirchandani A, Emberton M, Van Hemelrijck M, Grigoriadis A.

Oncotarget. 2018 Feb 5;9(16):12812-12824. doi: 10.18632/oncotarget.24400. eCollection 2018 Feb 27.

33.

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.

Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.

BMJ Open. 2018 Mar 16;8(3):e020787. doi: 10.1136/bmjopen-2017-020787.

34.

Determinants of cancer screening awareness and participation among Indonesian women.

Anwar SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, Watkins J, Wulaningsih W; PILAR Research Network.

BMC Cancer. 2018 Mar 6;18(1):208. doi: 10.1186/s12885-018-4125-z.

35.

Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.

Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, Van Hemelrijck M.

BMC Cancer. 2018 Feb 20;18(1):205. doi: 10.1186/s12885-018-4111-5.

36.

A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, Adolfsson J, Stattin P, Carroll P, Van Hemelrijck M.

Ecancermedicalscience. 2018 Jan 25;12:802. doi: 10.3332/ecancer.2018.802. eCollection 2018. Review.

37.

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M.

Oncotarget. 2017 Dec 4;9(1):774-782. doi: 10.18632/oncotarget.22891. eCollection 2018 Jan 2.

38.

Recent advances in understanding and managing aortic stenosis.

Van Hemelrijck M, Taramasso M, De Carlo C, Kuwata S, Regar E, Nietlispach F, Ferrero A, Weber A, Maisano F.

F1000Res. 2018 Jan 16;7:58. doi: 10.12688/f1000research.11906.1. eCollection 2018. Review.

39.

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.

Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett CE, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer JF, Arnold JN.

Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16.

40.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

41.

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

BJU Int. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. Epub 2018 Jan 18.

42.

Human development and its impact on genitourinary cancers.

Van Hemelrijck M.

BJU Int. 2017 Dec;120(6):747-748. doi: 10.1111/bju.13914. No abstract available.

43.

King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).

Saifuddin SR, Devlies W, Santaolalla A, Cahill F, George G, Enting D, Rudman S, Cathcart P, Challacombe B, Dasgupta P, Galustian C, Chandra A, Chowdhury S, Gillett C, Van Hemelrijck M.

BMC Cancer. 2017 Nov 22;17(1):784. doi: 10.1186/s12885-017-3773-8.

44.

A comparison of the left thoracoabdominal and Ivor-Lewis esophagectomy.

Davies AR, Zylstra J, Baker CR, Gossage JA, Dellaportas D, Lagergren J, Findlay JM, Puccetti F, El Lakis M, Drummond RJ, Dutta S, Mera A, Van Hemelrijck M, Forshaw MJ, Maynard ND, Allum WH, Low D, Mason RC.

Dis Esophagus. 2018 Mar 1;31(3). doi: 10.1093/dote/dox129.

PMID:
29087474
45.

The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.

Sheill G, Brady L, Guinan E, Hayes B, Casey O, Greene J, Vlajnic T, Cahill F, Van Hemelrijck M, Peat N, Rudman S, Hussey J, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, Mucci L, Sheils O, O'Leary J, O'Donnell DM, McDermott R, Finn S.

Trials. 2017 Oct 4;18(1):456. doi: 10.1186/s13063-017-2201-3.

46.

Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.

Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M.

BJU Int. 2018 Feb;121(2):260-267. doi: 10.1111/bju.14023. Epub 2017 Oct 17.

47.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

48.

Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.

Lee SM, Liyanage SH, Wulaningsih W, Wolfe K, Carr T, Younis C, Van Hemelrijck M, Popert R, Acher P.

Urol Oncol. 2017 Nov;35(11):664.e11-664.e18. doi: 10.1016/j.urolonc.2017.07.018. Epub 2017 Aug 8.

PMID:
28801025
49.

Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?

Van Hemelrijck M, Karagiannis SN, Rohrmann S.

Cancer Immunol Immunother. 2017 Dec;66(12):1557-1562. doi: 10.1007/s00262-017-2048-1. Epub 2017 Aug 9.

50.

Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal Biopsies.

Marra G, Eldred-Evans D, Challacombe B, Van Hemelrijck M, Polson A, Pomplun S, Foster CS, Brown C, Cahill D, Gontero P, Popert R, Muir G.

Urol Int. 2017;99(2):168-176. doi: 10.1159/000471491. Epub 2017 Jul 29.

PMID:
28768264

Supplemental Content

Loading ...
Support Center